← back to search

Wen‐Jia Zuo

Shanghai Medical College of Fudan University · CN
Area of research
Cancer Research · Oncology
Research interest
Research interests include HER2/EGFR in Cancer Research, Breast Cancer Treatment Studies, Monoclonal and Polyclonal Antibodies Research, and Advanced Breast Cancer Therapies.
h-index
15
citations
645
works
43
NIH funding
primary concept
email

Recent publications

Mobilizing antigen-presenting mast cells in anti-PD-1-refractory triple-negative breast cancer: a phase 2 trial
Nature Medicine 2025cited by 21position: middledoi
QL1209 (pertuzumab biosimilar) versus reference pertuzumab plus trastuzumab and docetaxel in neoadjuvant treatment for HER2-positive, ER/PR-negative, early or locally advanced breast cancer: A multicenter, randomized, double-blinded, parallel-controlled, phase III equivalence trial
British Journal of Cancer 2024cited by 5position: firstdoi
Tumor Size Still Impacts Prognosis in Breast Cancer With Extensive Nodal Involvement
Frontiers in Oncology 2021cited by 47position: middledoi
Genomic and Transcriptomic Landscape of Triple-Negative Breast Cancers: Subtypes and Treatment Strategies
Cancer Cell 2019cited by 1,082position: middledoi
The endogenous retrovirus-derived long noncoding RNA TROJAN promotes triple-negative breast cancer progression via ZMYND8 degradation
Science Advances 2019cited by 141position: middledoi
Characterization of PIK3CA and PIK3R1 somatic mutations in Chinese breast cancer patients
Nature Communications 2018cited by 183position: middledoi
Comprehensive transcriptome analysis identifies novel molecular subtypes and subtype-specific RNAs of triple-negative breast cancer
Breast Cancer Research 2016cited by 217position: middledoi
Dual Characteristics of Novel HER2 Kinase Domain Mutations in Response to HER2-Targeted Therapies in Human Breast Cancer
Clinical Cancer Research 2016cited by 75position: firstdoi
An Elevated Peripheral Blood Lymphocyte-to-Monocyte Ratio Predicts Favorable Response and Prognosis in Locally Advanced Breast Cancer following Neoadjuvant Chemotherapy
PLoS ONE 2014cited by 113position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Zhi-Min Shao · Fudan University6 papers (2016–2025)Yi‐Zhou Jiang · Nanjing Agricultural University4 papers (2016–2025)Xiao‐En Xu · Fudan University3 papers (2016–2019)Ke‐Da Yu · Fudan University3 papers (2016–2019)Yi‐Rong Liu · Northwestern University3 papers (2016–2019)Jiong Wu · Shanghai Medical College of Fudan University3 papers (2014–2016)Xin Hu · Fudan University3 papers (2016–2019)Gen‐Hong Di · Fudan University3 papers (2016–2019)Xianghuo He · Fudan University2 papers (2016–2019)Xi Jin · Palo Alto University2 papers (2016–2019)Zhi‐Ming Shao · Shanghai Medical College of Fudan University2 papers (2014–2018)Guang‐Yu Liu · Shanghai Medical College of Fudan University2 papers (2016–2016)Shuang Hao · Sun Yat-sen University2 papers (2016–2021)Da‐Qiang Li · Fudan University2 papers (2016–2019)Sheng‐Li Huang · Beijing Institute of Technology1 papers (2019–2019)Xiaopeng Ma · Wannan Medical College1 papers (2024–2024)Guohong Hu · Huazhong University of Science and Technology1 papers (2019–2019)Yongzhong Yao · Nanjing Medical University1 papers (2024–2024)Jianghua Ou · Xinjiang Medical University1 papers (2024–2024)Zhaofeng Niu · Shanxi Medical University1 papers (2024–2024)